₹311 Cr Block Deal: Pharma stock jumps 4% after 72 Lakh shares changed hands

Synopsis: Akums Drugs & Pharmaceuticals witnessed a block deal of 72.78 lakh shares (4.62% equity) worth Rs. 311.5 crore at Rs. 428 per share, highlighting strong institutional interest and boosting the stock price over 4% in today’s session.

The shares of pharmaceutical contract development and manufacturing organisations (CDMO) offering a comprehensive range of pharmaceutical products and services are now in the spotlight after 4.62% equity changed hands.

With a market capitalisation of Rs. 6,936 cr, the shares of Akums Drugs & Pharmaceuticals Ltd are currently trading at Rs. 441 per share, increasing more than 4% in today’s market session, making a high of Rs. 446.50, up from its previous close of Rs. 427.60 per share.

Block Deal

In a recent block deal, 72.78 lakh shares of Akums Drugs & Pharmaceuticals, representing 4.62% of the company’s equity, were traded at Rs. 428 per share, totalling approximately Rs. 311.5 crore. 

Block deals are large-volume trades conducted off-market, usually between institutional investors, and indicate significant strategic or institutional interest without immediately impacting the stock’s market price.

About the company 

Akums Drugs & Pharmaceuticals Ltd is an Indian pharmaceutical company engaged in the manufacturing and marketing of generic formulations, active pharmaceutical ingredients (APIs), and contract manufacturing services. The company serves domestic and international markets, supplying a wide range of therapeutic products and expanding its global presence.

The company reported a YoY decline in Q2FY26, with sales falling 1.5% to Rs. 1,018 crore from Rs. 1,033 crore in Q2FY25. EBIDT decreased 22% to Rs. 94.5 crore, while net profit dropped 36% to Rs. 42.7 crore. EPS declined 37.5% to Rs. 2.59. 

It has demonstrated strong financial performance, with a ROCE of 16.2% and a ROE of 17.2%. The stock trades at a P/E of 22.6 compared to the industry average of 30.7, with a low debt-to-equity ratio of 0.03. The company has also delivered impressive profit growth of 48.9% CAGR over the last five years, reflecting robust operational efficiency and growth potential.

Written by Manideep Appana

Disclaimer

The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Trade Brains Technologies Private Limited or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.

The post ₹311 Cr Block Deal: Pharma stock jumps 4% after 72 Lakh shares changed hands appeared first on Trade Brains.